全文2179字,阅读约需7分钟,帮我划重点划重点01博瑞医药的自主研发的GLP-1和GIP受体双重激动剂BGM0504注射液在美国的专利申请已获得批准,为其“出海”战略打下基础。02BGM0504在治疗18周后,相比安慰剂组HbA1c较基线平均降幅为2.76%,优于司美格鲁肽和替尔泊肽的数据。03由于GLP-1专利之争的紧张形势,博瑞医药投资者曾担心BGM0504的专利申请是否能顺利落地。04然而...
Source Link全文2179字,阅读约需7分钟,帮我划重点划重点01博瑞医药的自主研发的GLP-1和GIP受体双重激动剂BGM0504注射液在美国的专利申请已获得批准,为其“出海”战略打下基础。02BGM0504在治疗18周后,相比安慰剂组HbA1c较基线平均降幅为2.76%,优于司美格鲁肽和替尔泊肽的数据。03由于GLP-1专利之争的紧张形势,博瑞医药投资者曾担心BGM0504的专利申请是否能顺利落地。04然而...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.